ADC TOXICITY ATLAS
Payloads & linkers
Payload · Topoisomerase I inhibitor

Rezetecan (SHR9265 / SHR169265)

TopoI inhibitor

CCC1(C2=C(COC1=O)C(=O)N3CC4=C5C(CCC6=C5C(=CC(=C6C)F)N=C4C3=C2)NC(=O)C(C7CC7)O)O
Physicochemistry

Properties

MW
533.55 Da
XLogP3
3.67
logD₇.₄
1.89
TPSA
129 Ų
pKa
-
Charge pH 7.4
+1
H-bond donors
3
H-bond acceptors
8
Bystander
Yes
PubChem CID
172874939
Bioactivity
Payload SHR9265/SHR169265 is a DNA topoisomerase I (TOP1) inhibitor (exatecan-derived camptothecin; TOP1 inhibition comparable to SHR167971/DXd-class). ADC SHR-A1811 (DAR ~6) cytotoxicity IC50 0.3-2.32 nM across nine cancer cell lines; bystander killing IC50 0.23 +/- 0.05 nM on H
1 agent

ADCs built on this payload

Agent · target
Ocular
Hepatic
Neutrop.
Thrombo.
Anemia
GI
ILD
Neuro.
Trastuzumab rezetecanERBB2
3.3
42.9
79.4
42.9
76.2
79.4
11.6
0%severity100%
0
Assessed · clear
true 0%
No data
never assessed